What exactly is it?

The term collagen has become a true marketing argument. However, it actually covers two very different products, with incomparable mechanisms of action and levels of evidence.

In the context of canine osteoarthritis, it is essential to distinguish between:

• hydrolyzed collagen;
• undenatured type II collagen (UC-II®).

Presenting them as two versions of the same product is a mistake.

Hydrolyzed collagen is obtained from animal collagen fragmented into small peptides to be more easily digested and absorbed. The idea is to provide the body with peptides that can contribute to the maintenance of joint tissues.

UC-II, on the other hand, retains its natural structure. Its interest is not based on providing "materials" to the cartilage, but on an immunological mechanism called oral tolerance, which could modulate certain reactions involved in osteoarthritis.

In other words, these two products pursue the same objective (improving joint comfort) but do not act in the same way at all.

How are they supposed to work?

For hydrolyzed collagen, peptides from digestion pass into the bloodstream. Experimental studies show that some could act on cartilage cells (chondrocytes) and contribute to the maintenance of the cartilage matrix.

This mechanism is biologically plausible, but it alone does not prove clinical improvement in an arthritic dog. This is the difference between an effect observed in the laboratory and a demonstrated benefit in the animal.

UC-II works on a different principle. By remaining undenatured, it could induce immune tolerance in the gut, which would explain why a dose of only a few milligrams can produce a clinical effect.

In summary:

• Hydrolyzed collagen: provides peptides that can support cartilage.
• UC-II: acts through an immunological mechanism.

These two approaches are therefore not interchangeable.

What the studies actually show

Hydrolyzed collagen

The data is encouraging but remains limited.

The review by Blees et al. (2025) concludes that several studies report an improvement in certain parameters, such as mobility or comfort, but that the evidence is still insufficient to consider hydrolyzed collagen as a treatment with solidly established efficacy.

The study by Dobenecker et al. (2024) points in the same direction: dogs suffering from osteoarthritis showed an improvement in gait and quality of life after supplementation with specific collagen peptides.

However, these results concern a specific product and a particular protocol. They do not allow us to state that all supplements containing hydrolyzed collagen will have the same effects.

Today, the most rigorous conclusion is therefore the following: hydrolyzed collagen is an interesting avenue, but the evidence is still incomplete.

UC-II

The data is more robust than for hydrolyzed collagen.

The study by D'Altilio et al. showed a decrease in several indicators of pain and lameness in arthritic dogs supplemented with UC-II.

A few years later, Gupta et al. also observed an improvement in pain and joint function, measured by force plate. In this trial, the results were more favorable than those obtained with the glucosamine/chondroitin combination.

The study by Stabile et al. (2019) compared UC-II to robenacoxib, a veterinary anti-inflammatory. Both groups showed an improvement in the mobility score (LOAD). However, this does not mean that UC-II replaces an anti-inflammatory: it simply indicates that, in this specific study and with this evaluation criterion, the results were comparable.

Finally, the meta-analysis by Barbeau-Grégoire et al. (2022) places collagen-based supplements among the options with potential interest, but with a lower level of evidence than omega-3s. However, this analysis groups very different products, without always distinguishing hydrolyzed collagen from UC-II, which complicates its interpretation.

Currently, UC-II is therefore the type of collagen that benefits from the most convincing veterinary data.

What dose to use?

For hydrolyzed collagen, there is no universally recognized dose in dogs. Studies use different products, composed of different peptides and administered at variable doses. It is therefore impossible to define a reference dosage today.

For UC-II, the situation is simpler: most clinical trials use approximately 10 mg per day, a dose consistent with its mechanism of action.

Bioavailability: an often misunderstood point

Hydrolyzed collagen is designed to be easily absorbed as small peptides. This good absorption is well demonstrated.

However, good absorption does not automatically mean that a clinical benefit is guaranteed. This is precisely what studies are still trying to confirm.

UC-II, on the other hand, must retain its natural structure to function. If the collagen is denatured during manufacturing, the supposed oral tolerance mechanism disappears.

In other words, not all supplements simply labeled "type II collagen" are necessarily true UC-II products.

Marketing and scientific reality

Marketing maintains several confusions.

The first is to use the word collagen without specifying which product it is. However, comparing a hydrolyzed collagen dosed in grams to a UC-II dosed in a few milligrams makes no sense: they do not act in the same way.

The second is the promise of cartilage regeneration. To date, no veterinary study allows us to state that an oral supplement rebuilds the cartilage of an arthritic dog. Research rather suggests a potential support for joint function and an improvement in certain clinical signs.

Finally, some advertisements present laboratory results as proof of efficacy in dogs. However, a biological hypothesis, no matter how credible, never replaces a clinical trial.

In summary:

• UC-II: currently the most convincing level of evidence.
• Hydrolyzed collagen: promising results, but still insufficient to conclude definitively.

For which dogs?

UC-II seems particularly interesting in dogs with mild to moderate osteoarthritis, as a complement to comprehensive management: weight control, appropriate physical activity, treatments prescribed by the veterinarian and, if necessary, rehabilitation.

Its effect is progressive. Studies show improvement after several weeks, not a few days.

Hydrolyzed collagen can also play a role in this approach, but with more caution. The results are encouraging, without being yet solid enough to make it a supplement whose efficacy is clearly demonstrated.

In any case, none of these products replaces veterinary treatment when a dog suffers from severe or very painful osteoarthritis.

Precautions

Both forms of collagen generally show a good tolerance profile in the available studies.

The main point of vigilance concerns their origin. Depending on the manufacturers, collagen can come from chicken, beef, fish or other animal sources.

In a dog suffering from a confirmed food allergy, this origin must therefore be taken into account when choosing the supplement.

Key takeaways

The term "collagen" does not refer to a single product. Behind this word lie two very different approaches.

Hydrolyzed collagen provides peptides that can support joint tissues. The first results are encouraging, but the evidence is still limited and it is too early to talk about clearly demonstrated efficacy.

UC-II, on the other hand, currently benefits from a more robust level of evidence in dogs. Several clinical trials show an improvement in pain and mobility, making it an interesting option in a multimodal approach to osteoarthritis.

In all cases, one must remain vigilant regarding commercial promises. No study has shown that an oral supplement can regenerate the cartilage of an arthritic dog. The observed benefits mainly concern comfort, mobility and quality of life.

The choice of a supplement should therefore not be limited to the presence of the word "collagen" on the label, but should be based on the nature of the product, the quality of available studies and the dog's needs.

Sources 

1. Barbeau-Grégoire M. et al. (2022). A Systematic Review and Meta-Analysis of Enriched Therapeutic Diets and Nutraceuticals in Canine and Feline Osteoarthritis. 
2. Blees N.R. et al. (2025). Collagen Hydrolysates as Nutritional Support in Canine Osteoarthritis: A Narrative Review. 
3. D’Altilio M. et al. (2007). Therapeutic Efficacy and Safety of Undenatured Type II Collagen Singly or in Combination with Glucosamine and Chondroitin in Arthritic Dogs. 
4. Gupta R.C. et al. (2012). Comparative therapeutic efficacy and safety of type-II collagen (UC-II), glucosamine and chondroitin in arthritic dogs: pain evaluation by ground force plate. 
5. Stabile M. et al. (2019). Evaluation of the Effects of Undenatured Type II Collagen (UC-II) as Compared to Robenacoxib on the Mobility Impairment Induced by Osteoarthritis in Dogs. 
6. Dobenecker B. et al. (2024). The oral intake of specific Bioactive Collagen Peptides (BCP) improves gait and quality of life in canine osteoarthritis patients. 
7. Martínez-Puig D. et al. (2023). Collagen Supplementation for Joint Health: The Link between Composition and Scientific Knowledge.
8. Gencoglu H. et al. (2020). Undenatured Type II Collagen (UC-II) in Joint Health and Disease: A Review on the Current Knowledge of Companion Animals.